TRex Bio Inc.
TRex Bio Inc.
Your view on TRXB
Overview
What the company does, where it operates, and who runs it.
About TRex Bio Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Marion Johnston Erwin
- Headquarters
- 269 E. Grand Ave., Suite 300, South San Francisco, CA, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Marion Johnston Erwin
- Headquarters
- 269 E. Grand Ave., Suite 300, South San Francisco, CA, US
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines.
The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for TRex Bio Inc. from FRC's valuation model, read against the market price. TRXB last traded at $9.39; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for TRex Bio Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for TRex Bio Inc.. TRex Bio Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for TRex Bio Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.66 | -$0.53 | -$4.28 | -$2.17 |
| Low estimate | -$0.80 | -$0.53 | -$5.89 | -$2.48 |
| High estimate | -$0.53 | -$0.53 | -$2.84 | -$1.73 |
| No. of analysts | 1 | 1 | 2 | 2 |
| Year-ago EPS | — | — | — | — |
| Growth | — | — | — | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Low estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| High estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| No. of analysts | 0 | 0 | 0 | 0 |
| Year-ago revenue | — | — | — | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 19, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for TRex Bio Inc.. TRex Bio Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
More Medical - Pharmaceuticals companies
Market cap
- PBHPrestige Consumer Healthcare Inc.NYSE$2.4B
- PKBFFPeakBirch Commerce Inc.OTC$545M
- PLWYPeoplesway.com Inc.OTC$1,508
- PNDHFPond Technologies Holdings Inc.OTC$684,738
- PNPLPineapple, Inc.OTC$6M
- POMPOMDOCTOR LtdNASDAQ$14M
- PRPHProPhase Labs, Inc.NASDAQ$331,590
- PXYNPraxsyn CorporationOTC$6,347
- QMDTQuick-Med Technologies, Inc.OTC$11,204
- RADLYRaia Drogasil S.A.OTC$8.8B
- RBIIRising BioSciences, Inc.OTC$4,991
- RCDTFRecordati Industria Chimica e Farmaceutica S.p.A.OTC$11.6B
ETFs holding TRex Bio Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
- VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
- VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.00%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
- VTHRVanguard Russell 3000 ETF$4.9B in assets0.00%
Largest holders first, then the funds most concentrated in TRXB.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold TRex Bio Inc., and how their positions are changing. At a $78.2M market value, institutional positions materially move TRex Bio Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by TRex Bio Inc. executives and directors. Shares of TRex Bio Inc. have traded between $9.06 and $16.56 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming TRex Bio Inc.. TRex Bio Inc. is a $78.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming TRex Bio Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for TRex Bio Inc.. Coverage tracks TRex Bio Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of TRex Bio Inc.